TriSalus Life Sciences, Inc. (NASDAQ: TLSI) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $10.00 price target on the stock.
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $12.00 to $11.00. They now have a "buy" rating on the stock.
TriSalus Reports Q3 2024 Financial Results and Provides Business Update [Yahoo! Finance]
TriSalus Reports Q3 2024 Financial Results and Provides Business Update
TriSalus Life Sciences Inc (TLSI) Q3 2024 Earnings Report Preview: What To Look For [Yahoo! Finance]